Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study
Open Access
- 17 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , 623-633
Abstract
Background: Guidelines state that all hospitalized children with suspected or confirmed influenza receive prompt treatment with influenza-specific antivirals. We sought to determine the frequency of, and factors associated with, antiviral receipt among hospitalized children. Methods: We conducted active surveillance of children presenting with fever or respiratory symptoms from 1 December 2016 to 31 March 2020 at 7 pediatric medical centers in the New Vaccine Surveillance Network. The cohort consisted of children hospitalized with influenza A or B confirmed by clinical or research testing. The primary outcome was frequency of antiviral receipt during hospitalization. We used logistic regression to obtain adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for factors associated with antiviral receipt. Results: A total of 1213 children with laboratory-confirmed influenza were included. Overall, 652 children (53.8%) received an antiviral. Roughly 63.0% of children received clinical influenza testing. Among those with clinical testing, 67.4% received an antiviral. Factors associated with higher odds of antiviral receipt included hematologic (aOR = 1.76; 95% CI = 1.03–3.02) or oncologic/immunocompromising (aOR = 2.41; 95% CI = 1.13–5.11) disorders, prehospitalization antiviral receipt (aOR = 2.34; 95% CI = 1.49–3.67), clinical influenza testing (aOR = 3.07; 95% CI = 2.28–4.14), and intensive care unit admission (aOR = 1.53; 95% CI = 1.02–2.29). Symptom duration >2 days was associated with lower odds of antiviral treatment (aOR = 0.40; 95% CI = .30–.52). Antiviral receipt varied by site with a 5-fold difference across sites. Conclusions: Almost half of children hospitalized with influenza did not receive antivirals. Additional efforts to understand barriers to guideline adherence are crucial for optimizing care in children hospitalized with influenza.Keywords
Funding Information
- Centers for Disease Control and Prevention (K23 AI168496)
- National Institute for Allergy and Infectious Diseases
- National Institutes of Health
This publication has 50 references indexed in Scilit:
- Accuracy of Influenza ICD-10 Diagnosis Codes in Identifying Influenza Illness in ChildrenJAMA Network Open, 2024
- Population-Based Incidence of Influenza-Associated Serious Neuropsychiatric Events in Children and AdolescentsJAMA Pediatrics, 2023
- Household Transmission of Influenza A Viruses in 2021-2022JAMA, 2023
- Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020JAMA Pediatrics, 2022
- Assessment of Temporal Patterns and Patient Factors Associated With Oseltamivir Administration in Children Hospitalized With Influenza, 2007-2020JAMA Network Open, 2022
- Prevalence, Risk Factors, and Outcomes of Influenza-Associated Neurologic Complications in ChildrenThe Journal of Pediatrics, 2021
- Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and ChildrenJAMA Network Open, 2021
- Limited and Variable Use of Antivirals for Children Hospitalized With InfluenzaJAMA Pediatrics, 2017
- Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza VaccinationJAMA, 2015
- Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in ArgentinaIntensive Care Medicine, 2010